Olink Proteomics

We're #hiring a new Business Development Manager HighPlex - Nordics in Greater Helsingborg Metropolitan Area. Apply today or share this post with your network.

The power of protein signatures to predict disease outcomes and guide clinical decision making is graphically illustrated in the subject of this #weeklyread. Children with potential celiac disease (PCD) who present with serological but not intestinal structure symptoms, may or may not go on to develop the villous atrophy (VA) that characterizes celiac disease. This makes the decision of whether to commit them to a lifelong gluten-free diet a difficult clinical decision, with invasive biopsies than provide less than 80% accuracy the currently best option. A study from University of Naples Federico II measured baseline serum proteomics in children with PCD using the Olink® Target 96 Inflammation panel and compared individuals who did or didn’t develop celiac disease over a follow-up period of ~6 years. Key highlights • 9 markers were significantly differentially expressed in individuals who developed celiac disease, with principle component analysis clearly discriminating the two groups based on proteomics. • Multivariate analysis identified a 7-protein signature that predicted whether or not an individual would go on to develop celiac disease with an accuracy of over 95%. • Pathway analysis of these markers suggested that in individuals who will go on to develop celiac disease, gluten-induced inflammation and leukocyte differentiation are already underway even at the PCD stage. These findings show that a minimally invasive serum protein profile can predict development of celiac disease in children with PCD with great accuracy, up to at least 6 years prior to clinical diagnosis. The authors concluded, “The different expressions of these proteins are able to differentiate children with PCD who will develop VA with an accuracy of >95%. This appears to be sufficient to immediately suggest a gluten-free diet in children with PCD, who are almost certainly committed to developing VA”. Read the article: https://bit.ly/3NRU9v0 #olink #proteomics #precisionmedicine #celiacdisease

#AAEV24 #Olink #proteomics

Today, Dr. Eva Schmidt, is presenting a poster (and practicing yoga) at ASHG 2024. She will be presenting on the PRIDE Affinity-proteomics Archive (PRIDE-AP). The PRIDE is a centralized, standards-compliant, public data repository for mass spectrometry proteomics data and now Affinity proteomics (AP). When asked what makes her proud to stand by this poster today, Dr. Eva Schmidt said, "This marks an important milestone towards making Olink data easier to publish in journals and share the actual data with others." Good luck at your poster presentation, Eva! Learn more and start publishing today: https://bit.ly/40A778o #ASHG24

What is the key to choosing the right protein biomarker? And how can we ensure that our protein analysis combines thorough validation and precision with robust assay performance? Don’t miss our upcoming webinar as we explore: - Challenges and opportunities in developing assays that capture true biological signals in protein measurements. - Statistical analysis considerations to detect meaningful differences and generate actionable insights. - The power of utilizing scalable methods to streamline biomarker development. Register now https://bit.ly/3CcpTbQ

Welcome to the Olink Certified Service Provider Network, CheckImmune! CheckImmune, a spin-off from Charité - Universitätsmedizin Berlin, specializes in biomarker studies, it focuses on novel immunotherapeutics, including small molecules, biologics, and Advanced Therapy Medicinal Products (ATMPs), along with immunological challenges across various medical fields. With ISO 17025 and 15189 accreditations and adherence to GCLP (Good Clinical Laboratory Practice) standards, CheckImmune ensures high-quality results. Start planning your Olink project with CheckImmune today: https://hubs.la/Q02WkG9d0 #OlinkCertifiedServiceProviders

Ready to bring your proteomics discoveries to the clinic? Join our upcoming webinar, where our experts will guide you through the journey of bringing proteomics from discovery to the clinic. Learn how broad biomarker discovery can be scaled seamlessly to clinical applications, with real-world examples in Alzheimer's Disease and Multiple Sclerosis. We’re offering two sessions to fit your time zone, and our experts will be on hand to answer your questions live. Don’t miss out and register now! Date: November 19th Session 1: 9 AM GMT / 10 AM CET Session 2: 11 AM EST / 8 AM PST https://bit.ly/3AnXsHc

We're #hiring a new Business Development Manager MidPlex - South West UK in London, England. Apply today or share this post with your network.

Olink Proteomics, our team and partners are revving to go for ASHG 2024 that will take place in beautiful Denver Colorado in the Colorado Convention Center. Please join us at our CoLab event in Theatre 3 on Wed Nov 6 2:30-3pm MT where M. Austin Argentieri and our own Tony (Heng) Qian will join me to talk about the magic of combining multimomic data in population cohorts. At 3pm MT Evan Mills will lead our industry session that will include a panel discussion on Public Private Partnerships in Room 107 in the Colorado Convention Center. We will hear from Carlos Cruchaga, Joanna Howson, A. Gaye, Melissa Miller, Ryan Dhindsa, and last but certainly not least, Chris Whelan. Find our team at Booth #312 in the Exhibit Hall. We look forward to seeing many of you there!

This week we are at #SITC2024, the largest cancer immunotherapy conference, and naturally, we are thinking about what emerging technologies will have the biggest impact on immunotherapy research. What do you think? Of the technologies listed below which do you predict will have the biggest impact on immunotherapy research in the next 5 years? Have a different prediction? Leave your predictions in the comments.